ASX:GSS

Genetic Signatures Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive GSS News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Signatures and its competitors with MarketBeat's FREE daily newsletter.

About Genetic Signatures

Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in North America and Australia. The company designs and manufactures a suite of real-time polymerase chain reaction based products for detection of infectious diseases under EasyScreen brand name. It also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. Genetic Signatures Limited was founded in 2001 and is headquartered in Sydney, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Diagnostics & Research
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:GSS
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.geneticsignatures.com
Phone: 61 2 9870 7580
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: $28.38 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: A$0.35 per share
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.81
Current Ratio: 10.30
Quick Ratio: 7.68

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Genetic Signatures.

0.0 Community Rank

Outperform Votes
Genetic Signatures has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Genetic Signatures has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Genetic Signatures and other stocks. Vote “Outperform” if you believe GSS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GSS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Genetic Signatures does not currently pay a dividend.
Dividend Growth
Genetic Signatures does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genetic Signatures insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Genetic Signatures (ASX:GSS) Frequently Asked Questions

What stocks does MarketBeat like better than Genetic Signatures?: Wall Street analysts have given Genetic Signatures a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genetic Signatures wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
Who are Genetic Signatures' key executives?: Genetic Signatures' management team includes the following people:
Dr. John R. Melki, MD, CEO & Exec. Director
Mr. Peter Manley, CFO & Company Sec.
Mr. Michael Anton Aicher M.B.A., BSc, MBA, Exec. Director of US Operations & Exec. Director (Age 61, Pay $178.1k)
Mr. Christopher M. Abbott, Founder & Chairman Emeritus
Dr. Douglas S. Millar BSc, Ph.D., Chief Scientific Officer
Mr. Jackson Jones, Director of Global Sales & Marketing
Mr. Patrick Noland BSc, MBA, US Market Consultant
Who are some of Genetic Signatures' key competitors?: Some companies that are related to Genetic Signatures include Australian Clinical Labs (ACL), BARD1 Life Sciences (BD1), Biomark Diagnostics (BUX), Charles River Laboratories International (CRL), Cryosite (CTE), dorsaVi (DVL), Epigenomics (EPGNY), Eternity Healthcare (ETAH), Genetic Technologies (GTG), Imagin Medical (IME), Imagion Biosystems (IBX), Integral Diagnostics (IDX), Lifespot Health (LSH), Med BioGene (MBGNF) and Medical Imaging (MEDD).
View all of GSS's competitors.
What is Genetic Signatures' stock symbol?: Genetic Signatures trades on the ASX under the ticker symbol "GSS."
How much money does Genetic Signatures make?: Genetic Signatures has a market capitalization of $0.00 and generates $28.38 million in revenue each year.
How many employees does Genetic Signatures have?: Genetic Signatures employs 1,626 workers across the globe.
What is Genetic Signatures' official website?: The official website for Genetic Signatures is www.geneticsignatures.com.
Where are Genetic Signatures' headquarters?: Genetic Signatures is headquartered at 333 Bay Street, Toronto, Ontario M5H 2T6.
How can I contact Genetic Signatures?: Genetic Signatures' mailing address is 333 Bay Street, Toronto, Ontario M5H 2T6. The company can be reached via phone at 61 2 9870 7580.

This page was last updated on 10/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.